Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Who's worth your money for Semaglutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 16 scored sellers
$976 · 200mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 10mg
Most tested
12 independent COAs on file
$130 · 20mg · 99.3% purity
Average price
$6.88/mg
Sellers
26
45-day trend
+3.4%
23 of 26 sellers have a current price· 5 stale hidden· 2 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 1h ago
$4.88/mg -29.1% vs avg$976
200mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 1h ago
$9.80/mg +42.5% vs avg$490
50mg
- 🇺🇸 Prime Peptides96
via Disclosed Labs · 1h ago
$7.50/mg +9% vs avg$150
20mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 1h ago
$6.50/mg -5.5% vs avg$130
20mg
- Nova Peptides94
via Disclosed Labs · 1h ago
$8.00/mg +16.3% vs avg$79.99
10mg
no purity - 🇺🇸 Polaris Peptides90
via Disclosed Labs · 1h ago
$8.25/mg +19.9% vs avg$165
20mg
- optimasupply.is86
via Disclosed Labs · 1h ago
$9.50/mg +38.1% vs avg$94.99
10mg
- 🇨🇳 Reta Peptide83
✓ verified at source · 1h ago
$6.50/mg -5.5% vs avg$65.00
10mg
- Modern Research Peptides82
via Disclosed Labs · 1h ago
$1.83/mg -73.4% vs avg$54.99
30mg
no purity - True Peptide82
via Disclosed Labs · 1h ago
$4.00/mg -41.9% vs avg$120
30mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Semaglutide
Get one email when the market actually moves — no newsletter, no noise.
About Semaglutide
CAS
910463-68-2
Molecular formula
C187H291N45O59
Typical dose range
0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks
Half-life
~7 days
COAs for Semaglutide
195 third-party tests across 30 vendors. Each card links to the full report.
For
Semaglutide
by VoriLabs· batch SEMA_2608-A
For
Semaglutide
by Velora Biolabs· batch VBL-SM20-1
For
Semaglutide
by Peptide Plugs· batch 189-02-DK
For
Semaglutide
by VoriLabs· batch VoriLabs SEMA-2607-C
For
Semaglutide
by VoriLabs· batch VoriLabs SEMA-2607-B
For
Semaglutide
by EZ Peptides· batch EZP-1P1007112026-04
For
Semaglutide
by Synthesis Peptides· batch 1G10826
For
Semaglutide
by Hydro Research Peptides· batch HR-2026-7341
For
Semaglutide
by Longeva· batch B-2026-SEMA-5-001
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by Soma Peptides· batch SEV052657
For
Semaglutide
by Certified Peptides· batch 260518SG53
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Blank Peptides· batch GS10-052026-4
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by Vertex Labs· batch SM0000038
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
For
Semaglutide
by Prime Peptides· batch 3272026SM
23 citations indexed for Semaglutide
Study · 2026
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy
Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are at risk for cardiometabolic complications and major adverse liver-related outcomes (MALO), including cirrhosis, cancer, and liver transplantation.
cohort · 2026
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.
Study · 2026
The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment
Objective This study aimed to evaluate the conventional and distributional cost-effectiveness of semaglutide, laparoscopic sleeve gastrectomy (LSG), and a "do nothing" option in Black and White racial subgroups.
Study · 2026
The impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study
Background Although laparoscopic sleeve gastrectomy (LSG) is an effective treatment for severe obesity, some patients experience suboptimal weight loss or an early weight-loss plateau during postoperative follow-up.
Study · 2026
Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis
Introduction Real-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR.
Study · 2026